MDP Insider Trading (Medexus Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$49,308.39
Insider Selling (Last 12 Months): C$0.00
Medexus Pharmaceuticals Share Price & Price History
Current Price: C$7.75
Price Change: ▼ Price Decrease of -0.4 (-4.91%)
As of 06/16/2021 01:00 AM ET
The Incredible Dividend Map... Where Stocks Yield 26% a Year!
What’s the highest-yielding stock you’ve ever owned?
The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
Medexus Pharmaceuticals Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/24/2021||Roland Boivin||Senior Officer||Buy||3,033||C$2.97||C$9,008.01||20,928|
|8/19/2021||Roland Boivin||Senior Officer||Buy||500||C$2.77||C$1,385.00||13,395|
|6/21/2021||Roland Boivin||Senior Officer||Buy||500||C$7.20||C$3,600.00||12,095|
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
SEC Filings (Institutional Ownership Changes) for Medexus Pharmaceuticals (CVE:MDP)
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Medexus Pharmaceuticals?